Cancer of the Lung And SeneScencE - Prospective Cohort 1
CLASSE-P1
Identification of Aging Biomarkers for Better Tailoring of Cancer Treatment in Older Patients With Lung Cancer: a Multicenter Clinico-biological Cohort Study
2 other identifiers
interventional
385
1 country
1
Brief Summary
The main objective is to identify and assess the predictive value of ageing and senescence biomarkers (methylome, telomeres, inflammageing) and senescent cells in tissues to improve prognosis assessment older patients with locally or locally-advanced Non-Small Cell Lung Cancer (NSCLC).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable nonsmall-cell-lung-cancer
Started Jul 2025
Longer than P75 for not_applicable nonsmall-cell-lung-cancer
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 17, 2025
CompletedFirst Posted
Study publicly available on registry
April 11, 2025
CompletedStudy Start
First participant enrolled
July 9, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2032
December 15, 2025
September 1, 2025
3 years
February 17, 2025
December 8, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Unplanned hospitalizations within 12 months
Number of unplanned hospitalizations within 12 months
12 months post surgery
Secondary Outcomes (9)
Mortality (all-cause) and cause-specific
Month 12 and Month 60 post surgery
Surgical Complications
Month 3 and Month 6 post surgery
Major Toxicities
Month 3 and Month 6 post surgery
Quality of Life Core 30
Month 6 and Month 12 post surgery.
Quality of Life Lung Cancer 13
Month 6 and Month 12 post surgery
- +4 more secondary outcomes
Interventions
Blood samples (5 ml) during surgery or within 3 days before.
Eligibility Criteria
You may qualify if:
- Patients 70 years and over
- Local or locally advanced (Clinic stage I-IIIA) NSCLC (clinically (or radiologically) suspected or histologically proven)
- Surgical Curative Intent
- Signed informed Consent (or signed by the curator or tutorship)
- Affiliated to social security administrative care service
You may not qualify if:
- Subject deprived of liberty by judicial or administrative decision or patient under guardianship
- Subject unable to understand the purpose and conditions of the study and unable to give consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Assistance Publique - Hôpitaux de Parislead
- ARC Foundation and Insermcollaborator
- URC-CIC Paris Descartes Necker Cochincollaborator
Study Sites (1)
Henri Mondor Hospital
Créteil, Île-de-France Region, 94000, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Florence CANOUÏ-POITRINE, PhD
Assistance Publique Hopitaux de Paris
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 17, 2025
First Posted
April 11, 2025
Study Start
July 9, 2025
Primary Completion (Estimated)
July 1, 2028
Study Completion (Estimated)
July 1, 2032
Last Updated
December 15, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will not share